Stock Track | Zai Lab Soars 6.45% in Pre-market on FDA Fast Track Designation for Zoci

Stock Track05-11

Zai Lab Ltd's stock surged 6.45% in pre-market trading on Monday, following positive regulatory news for its drug pipeline.

The biopharmaceutical company received the U.S. Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas. This regulatory status is intended to expedite the review and development of new drugs that address an unmet medical need or treat serious or life-threatening diseases.

The designation represents a significant milestone for Zai Lab's clinical development program and potentially accelerates the path to market for this therapeutic candidate. Zoci had previously been granted fast track designation for the treatment of extensive-stage small cell lung cancer in May 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118606375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118606375","market":"nz","top_or_hot":-1,"title":"Stock Track | Zai Lab Soars 6.45% in Pre-market on FDA Fast Track Designation for Zoci","media":"Stock Track","content":"<p>Zai Lab Ltd's stock surged 6.45% in pre-market trading on Monday, following positive regulatory news for its drug pipeline.</p><p>The biopharmaceutical company received the U.S. Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas. This regulatory status is intended to expedite the review and development of new drugs that address an unmet medical need or treat serious or life-threatening diseases.</p><p>The designation represents a significant milestone for Zai Lab's clinical development program and potentially accelerates the path to market for this therapeutic candidate. Zoci had previously been granted fast track designation for the treatment of extensive-stage small cell lung cancer in May 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zai Lab Soars 6.45% in Pre-market on FDA Fast Track Designation for Zoci</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zai Lab Soars 6.45% in Pre-market on FDA Fast Track Designation for Zoci\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab Ltd's stock surged 6.45% in pre-market trading on Monday, following positive regulatory news for its drug pipeline.</p><p>The biopharmaceutical company received the U.S. Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas. This regulatory status is intended to expedite the review and development of new drugs that address an unmet medical need or treat serious or life-threatening diseases.</p><p>The designation represents a significant milestone for Zai Lab's clinical development program and potentially accelerates the path to market for this therapeutic candidate. Zoci had previously been granted fast track designation for the treatment of extensive-stage small cell lung cancer in May 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZLAB","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1118606375","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118606375","pubTimestamp":1778501135,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zai Lab Ltd's stock surged 6.45% in pre-market trading on Monday, following positive regulatory news for its drug pipeline.The biopharmaceutical company received the U.S. Food and Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZLAB":"再鼎医药"},"translate_title":"个股赛道|Zoci获FDA快速通道认定再鼎医药盘前大涨6.45%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":1},"content_text":"Zai Lab Ltd's stock surged 6.45% in pre-market trading on Monday, following positive regulatory news for its drug pipeline.The biopharmaceutical company received the U.S. Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas. This regulatory status is intended to expedite the review and development of new drugs that address an unmet medical need or treat serious or life-threatening diseases.The designation represents a significant milestone for Zai Lab's clinical development program and potentially accelerates the path to market for this therapeutic candidate. Zoci had previously been granted fast track designation for the treatment of extensive-stage small cell lung cancer in May 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118606375","isCrawlerRequest":true}